+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Internal validity of clinical trials for Plasmodium vivax malaria treatment: analysis of evaluation study of in vivo Plasmodium vivax emergence of resistance to standard doses of primaquine



Internal validity of clinical trials for Plasmodium vivax malaria treatment: analysis of evaluation study of in vivo Plasmodium vivax emergence of resistance to standard doses of primaquine



Revista Da Sociedade Brasileira de Medicina Tropical 36(3): 383-386



Parasite resistance can be defined as the ability of a parasite strain to survive and/or to multiply despite the administration and absorption of a drug given in doses equal or higher than those usually recommended, but within the limits of tolerance of the patients. Therefore, the ideal study design to be used to monitor emergence of parasite resistance would use historical controls or any valid baseline data. Moreover, it is desirable to have some control of remaining determinants of therapeutic failure, not related to biological parasite resistance, which could vary over time and would have potential to distort the analysis for detecting emergence of parasite resistance. Here we comment on the internal validity of studies, which aim to assess the in vivo Plasmodium vivax emergence of resistance to standard doses of primaquine used routinely by health services. Few studies have paid attention to the need to control for other determinant factors of therapeutic failures or made any attempt to compare current findings with cure failure rates of historical controls from a given geographical area. Therefore, attention to the internal validity (and limitations) of study conclusions in these types of study is strongly advised.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 049379765

Download citation: RISBibTeXText

PMID: 12908040


Related references

In vivo trial for evaluation of chloroquine sensitivity of Plasmodium vivax isolates from Rondonia and efficacy of a new therapeutic schedules of association with primaquine for the treatment of P vivax malaria. Memorias do Instituto Oswaldo Cruz 93(Suppl. 2): 59-60, 1998

Studies on benign tertian malaria. I. On the occurrence of acquired tolerance to Plasmodium vivax. II. The clinical characteristics of the disease in relation to the dosage of sporozoites. III. On the absence of a heterologous tolerance to Plasmodium vivax. IV. On the refractoriness of negroes to inoculation with Plasmodium vivax. Amer. Journal of Hygiene 17: 55-59, 666-685; 18: 482-484, 485-489, 1933

Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. American Journal of Tropical Medicine and Hygiene 80(2): 188-193, 2009

Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis. Travel Medicine and Infectious Disease 13(3): 235-240, 2016

Prospective Study of Plasmodium vivax Malaria Recurrence after Radical Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo, Colombia. Antimicrobial Agents and ChemoTherapy 60(8): 4610-4619, 2016

Primaquine and relapses of Plasmodium vivax. Meta analysis of controlled clinical trials. Revista Brasileira de Epidemiologia 18(1): 174-193, 2016

Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004. Biomedica 26(3): 353-365, 2006

A case of Plasmodium vivax malaria: Primaquine resistance?. Mikrobiyoloji Bulteni 29(3): 296-298, 1995

Plasmodium vivax: prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan. Experimental Parasitology 127(1): 167-172, 2011

Drug resistance of Plasmodium falciparum and Plasmodium vivax strains in Cambodia (Cardamone Massif). Morphological characteristics of Plasmodium vivax. Medecine Tropicale 44(4): 339-349, 1984

Treatment of primaquine-resistant Plasmodium vivax malaria. Lancet 340(8814): 310-310, 1992

Primaquine treatment and relapse in Plasmodium vivax malaria. Pathogens and Global Health 110(1): 1-8, 2016

Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010). Journal of Travel Medicine 20(2): 134-136, 2013

Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days. Acta Tropica 112(2): 188-192, 2009

Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. Scandinavian Journal of Infectious Diseases 46(1): 63-65, 2014